initial public offerings (IPOs) trading on American exchanges

Wednesday, January 22, 2014

Evoke Pharma (EVOK) began trading on the NASDAQ on 25 September 2013

Jan 2014 update


Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.


Suite 385, 12555 High Bluff Drive
United States

Key stats and ratios

Q2 (Jun '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-55.40%-395.07%
Return on average equity--

No comments:

Post a Comment